id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1980-N-0036-0046,FDA,FDA-1980-N-0036,FDA/DDM to Martha D. Smith,Other,ACK-Acknowledgement Letter,2006-02-24T05:00:00Z,2006,2,,,2008-12-05T14:31:11Z,,0,0,09000064805b94ae
FDA-1980-N-0036-0045,FDA,FDA-1980-N-0036,"FDA/CDER to Willing Solutions, Inc.",Other,ACK-Acknowledgement Letter,2006-02-23T05:00:00Z,2006,2,,,2008-12-05T14:30:22Z,,0,0,09000064805b94ad
FDA-1980-N-0036-0025,FDA,FDA-1980-N-0036,Comparison of Cationic-Surfactant & Phenol-Based Mouthwash-Gargles In Relieving Oropharyngeal Pain,Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T17:39:55Z,,0,0,09000064805b9499
FDA-1980-N-0036-0036,FDA,FDA-1980-N-0036,"Coal Tar, Ultrviolet Light & Cancer",Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T18:03:00Z,,0,0,09000064805b94a4
FDA-1980-N-0036-0016,FDA,FDA-1980-N-0036,Phenol & It's Derivatives: The Relation Between Their Chemical Constitution & Their Effect on The Organism,Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T16:19:15Z,,0,0,09000064805b9490
FDA-1980-N-0036-0043,FDA,FDA-1980-N-0036,Skin Carcinoma In Patients With Psoriasis Treated With Topical Tar & Artificial Ultraviolet Radiation,Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T18:13:08Z,,0,0,09000064805b94ab
FDA-1980-N-0036-0042,FDA,FDA-1980-N-0036,Gynaseptic In The Treatment of Vaginitis,Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T18:11:31Z,,0,0,09000064805b94aa
FDA-1980-N-0036-0039,FDA,FDA-1980-N-0036,Structure of Povidone-Iodine,Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T18:06:47Z,,0,0,09000064805b94a7
FDA-1980-N-0036-0028,FDA,FDA-1980-N-0036,"Combined Steroid Antiinfective Topical Therapy In Common Dermatoses: A Double-Blind, Multi-Center Study of Iodochlorhydroxyquin-Hydrocortisone In 277 Patients",Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T17:47:21Z,,0,0,09000064805b949c
FDA-1980-N-0036-0019,FDA,FDA-1980-N-0036,Memorandum,Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T17:27:16Z,,0,0,09000064805b9493
FDA-1980-N-0036-0021,FDA,FDA-1980-N-0036,"Antimicrobial II Panel-27th Meeting-June 24th through 26th, 1977",Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T17:31:26Z,,0,0,09000064805b9495
FDA-1980-N-0036-0015,FDA,FDA-1980-N-0036,Percutaneous Absorption & Disposition of Iodochlorhydroxyquin In Dogs,Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T16:17:13Z,,0,0,09000064805b948f
FDA-1980-N-0036-0044,FDA,FDA-1980-N-0036,Percutaneous Absporption of Iodochlorhydroxyquin In Humans,Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T18:14:53Z,,0,0,09000064805b94ac
FDA-1980-N-0036-0041,FDA,FDA-1980-N-0036,Tolnaftate Powder In Prophylaxis of Tinea Pedis,Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T18:10:08Z,,0,0,09000064805b94a9
FDA-1980-N-0036-0034,FDA,FDA-1980-N-0036,Introductory Review of Subacute Myelo-Optico-Neuropathy (S. M. O. N.) & It's Studies Done By The S. M. O. N. Research Commission,Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T17:59:14Z,,0,0,09000064805b94a2
FDA-1980-N-0036-0026,FDA,FDA-1980-N-0036,An Epidemic of Infection with Trichophyton Tonsurans Revealed In A 20-Year Survey of Fungal Infections In Chicago,Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T17:43:30Z,,0,0,09000064805b949a
FDA-1980-N-0036-0017,FDA,FDA-1980-N-0036,Sterile Clindamycin Phosphate,Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T16:20:37Z,,0,0,09000064805b9491
FDA-1980-N-0036-0023,FDA,FDA-1980-N-0036,Clinical Evaluation of An Anesthetic Mouthwash,Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T17:36:39Z,,0,0,09000064805b9497
FDA-1980-N-0036-0024,FDA,FDA-1980-N-0036,Evaluation of An Antiseptic Anesthetic Solution,Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T17:37:42Z,,0,0,09000064805b9498
FDA-1980-N-0036-0038,FDA,FDA-1980-N-0036,Evaluation of Chloraseptic Solution As An Anesthetic Mouthwash,Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T18:05:36Z,,0,0,09000064805b94a6
FDA-1980-N-0036-0035,FDA,FDA-1980-N-0036,Incidence of Skin Cancers In Patients with Atopic Dermatitis Treated With Coal Tar: A 25-Year Follow-Up Study,Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T18:01:08Z,,0,0,09000064805b94a3
FDA-1980-N-0036-0020,FDA,FDA-1980-N-0036,Correspondence & Memorandums,Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T17:29:18Z,,0,0,09000064805b9494
FDA-1980-N-0036-0030,FDA,FDA-1980-N-0036,"Dermatologic Drugs Advisory Committee-26th Meeting-November 18, 1985",Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T17:51:21Z,,0,0,09000064805b949e
FDA-1980-N-0036-0018,FDA,FDA-1980-N-0036,Chloraderm In Tinca Pedis,Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T17:25:51Z,,0,0,09000064805b9492
FDA-1980-N-0036-0022,FDA,FDA-1980-N-0036,Clinical Evaluation of A New Halcinonide-Antifungal Combination,Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T17:35:34Z,,0,0,09000064805b9496
FDA-1980-N-0036-0040,FDA,FDA-1980-N-0036,Zur Kenntinis der antimikrobiellen Aktivitat von Breitspektrum-Antimikrobika unter besonderer Berucksichtigung der Salicylsaure,Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T18:08:44Z,,0,0,09000064805b94a8
FDA-1980-N-0036-0033,FDA,FDA-1980-N-0036,"Evaluation of Chloraderm As A Dermtologic Agent: A Study of Bacteriologic, Fungicidal & Antipuritic Properties",Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T17:56:53Z,,0,0,09000064805b94a1
FDA-1980-N-0036-0031,FDA,FDA-1980-N-0036,Cited References,Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T17:52:41Z,,0,0,09000064805b949f
FDA-1980-N-0036-0027,FDA,FDA-1980-N-0036,Prophylaxis of Tinea Pedis: Efficacy of Tolnaftate Powder & It's Talc-Constarch Base,Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T17:44:59Z,,0,0,09000064805b949b
FDA-1980-N-0036-0029,FDA,FDA-1980-N-0036,Tolnaftate As A Prophylactic Agent for Tinea Pedis,Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T17:49:58Z,,0,0,09000064805b949d
FDA-1980-N-0036-0037,FDA,FDA-1980-N-0036,Evaluation of Chloraseptic,Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T18:04:12Z,,0,0,09000064805b94a5
FDA-1980-N-0036-0032,FDA,FDA-1980-N-0036,"Evaluation of Chloraderm In The Topical Therapy of ""Athlete's Foot""",Supporting & Related Material,BKG-Background Material,2006-02-21T05:00:00Z,2006,2,,,2008-12-08T17:55:02Z,,0,0,09000064805b94a0